Safety, Tolerability and Pharmacokinetics of Single-Dose Oral SYHA1402 in Healthy Chinese Subjects

被引:0
作者
Beibei Liang
Jin Wang
Guanxuanzi Zhang
Rui Wang
Yun Cai
机构
[1] PLA General Hospital,Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center of Chinese
来源
Neurology and Therapy | 2023年 / 12卷
关键词
Aldose reductase inhibitor; Diabetic peripheral neuropathy; Pharmacokinetics; Safety;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:947 / 959
页数:12
相关论文
共 37 条
[1]  
Hodgkinson AD(2001)Aldose reductase expression is induced by hyperglycemia in diabetic nephropathy Kidney Int 60 211-218
[2]  
Søndergaard KL(1996)Oxidative stress and diabetic vascular complications Diabetes Care 19 257-267
[3]  
Yang B(1988)Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy N Engl J Med 319 542-548
[4]  
Giugliano D(1992)Complications: neuropathy, pathogenetic considerations Diabetes Care 15 1902-1925
[5]  
Ceriello A(1966)Sorbitol pathway: presence in nerve and cord with substrate accumulation in diabetes Science 151 209-210
[6]  
Paolisso G(1997)Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats Diabetologia 40 271-281
[7]  
Dyck PJ(2000)Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients Diabetes Care 23 1539-1544
[8]  
Zimmerman BR(2010)Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments Diabetes Care 33 2285-2293
[9]  
Vilen TH(2016)Glucotoxic mechanisms and related therapeutic approaches Int Rev Neurobiol 127 121-149
[10]  
Greene DA(2017)New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain Neuron 93 1296-1313